Reviva Pharmaceuticals (RVPH) Projected to Announce Earnings on Thursday

by · The Cerbat Gem

Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) will likely be releasing its Q2 2026 resultson Thursday, August 13th. Analysts expect Reviva Pharmaceuticals to post earnings of ($0.36) per share for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Monday, August 17, 2026 at 4:00 PM ET.

Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.10). On average, analysts expect Reviva Pharmaceuticals to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Reviva Pharmaceuticals Stock Up 4.7%

Shares of RVPH stock opened at $0.45 on Wednesday. The business’s fifty day moving average is $0.57 and its 200 day moving average is $1.85. The stock has a market cap of $5.90 million, a price-to-earnings ratio of -0.11 and a beta of 0.53. Reviva Pharmaceuticals has a twelve month low of $0.26 and a twelve month high of $17.20.

Institutional Trading of Reviva Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC grew its position in Reviva Pharmaceuticals by 6.9% during the 2nd quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock valued at $171,000 after purchasing an additional 29,063 shares during the last quarter. NewEdge Advisors LLC bought a new stake in Reviva Pharmaceuticals during the 1st quarter valued at about $58,000. XTX Topco Ltd raised its holdings in Reviva Pharmaceuticals by 63.6% in the fourth quarter. XTX Topco Ltd now owns 164,291 shares of the company’s stock worth $46,000 after buying an additional 63,893 shares during the last quarter. Lido Advisors LLC purchased a new position in Reviva Pharmaceuticals in the third quarter worth about $37,000. Finally, Millennium Management LLC lifted its stake in shares of Reviva Pharmaceuticals by 15.0% in the third quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock worth $631,000 after buying an additional 223,178 shares in the last quarter. 63.18% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

RVPH has been the topic of a number of research reports. Wall Street Zen upgraded shares of Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, July 5th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research report on Tuesday, April 21st. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $66.67.

Check Out Our Latest Analysis on RVPH

About Reviva Pharmaceuticals

(Get Free Report)

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.

Read More